COVID-19 vaccines and thrombosis with thrombocytopenia syndrome

  title={COVID-19 vaccines and thrombosis with thrombocytopenia syndrome},
  author={Chih-Cheng Lai and Wen-Chien Ko and Chih-Jung Chen and Po-Yen Chen and Yhu-Chering Huang and P.-I. Lee and Po-Ren Hsueh},
  journal={Expert Review of Vaccines},
  pages={1027 - 1035}
ABSTRACT Introduction To combat COVID-19, scientists all over the world have expedited the process of vaccine development. Although interim analyses of clinical trials have demonstrated the efficacy and safety of COVID-19 vaccines, a serious but rare adverse event, thrombosis with thrombocytopenia syndrome (TTS), has been reported following COVID-19 vaccination. Areas covered This review, using data from both peer-reviewed and non-peer-reviewed studies, aimed to provide updated information… 
COVID-19: State of the Vaccination
Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more, and efficacy is good, there are various barriers to their global use.


Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
It is recommended that treatment with platelet transfusions be avoided because of the risk of progression in thrombotic symptoms and that the administration of a nonheparin anticoagulant agent and intravenous immune globulin be considered for the first occurrence of these symptoms.
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Vaccination with Ch adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 can result in the rare development of immuneThrombotic thrombocytopenia mediated by platelet-activating antibodies against PF4, which clinically mimics autoimmune heparin-induced thromBocy topenia.
Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure
Early observations insinuate that the exposure to the “COVID-19 vaccine AstraZeneca” might trigger the expression of antiplatelet antibodies, resulting in a condition with thrombocytopenia and venous thromBotic events, and patients’ treatment should address the thrombo-embolic manifestations, the coagulation disorder, and the underlying immunological phenomena.
Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.
Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication.
Treatment options for COVID-19: The reality and challenges
Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or ang Elliotensin II type I receptor blockers is advised for COVID-19 patients.
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs
Traditional Chinese medicine with antiviral effects on SARS-CoV-2 and immune-modulation is widely used for COVID-19 patients in China, and is worthy of further studies.
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination – A report of two UK cases
Patients presenting with CVST features and thrombocytopenia post-vaccination should undergo PF4 antibody testing and be managed in a similar fashion to HIT, in particular avoiding heparin and platelet transfusions.
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Findings in five patients who presented with venous thrombosis andThrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19) suggest that they represent a rare vaccine-related variant of spontaneous heparin-induced thromBocytopensia.
Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine
This is the first reported case of DVT presenting as an adverse event post-SARS-CoV-2 vaccination, and the intense immunological response evoked by the second dose of vaccine could be a trigger for the thrombotic event described.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.